Lineage Cell Therapeutics/$LCTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Ticker
$LCTX
Sector
Primary listing
AMEX
Employees
75
Headquarters
Website
LCTX Metrics
BasicAdvanced
$394M
-
-$0.28
1.76
-
Price and volume
Market cap
$394M
Beta
1.76
52-week high
$2.09
52-week low
$0.37
Average daily volume
1.3M
Financial strength
Current ratio
5.204
Quick ratio
5.045
Long term debt to equity
3.613
Total debt to equity
5.581
Profitability
EBITDA (TTM)
-21.08
Gross margin (TTM)
-22.80%
Net profit margin (TTM)
-436.47%
Operating margin (TTM)
-149.62%
Effective tax rate (TTM)
7.69%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-12.06%
Return on equity (TTM)
-105.30%
Valuation
Price to revenue (TTM)
24.978
Price to book
8.62
Price to tangible book (TTM)
176.46
Price to free cash flow (TTM)
-18.702
Free cash flow yield (TTM)
-5.35%
Free cash flow per share (TTM)
-0.084
Growth
Revenue change (TTM)
53.24%
Earnings per share change (TTM)
197.02%
3-year revenue growth (CAGR)
-0.33%
10-year revenue growth (CAGR)
7.54%
3-year earnings per share growth (CAGR)
21.29%
10-year earnings per share growth (CAGR)
-7.39%
What the Analysts think about LCTX
Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.
LCTX Financial Performance
Revenues and expenses
LCTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lineage Cell Therapeutics stock?
Lineage Cell Therapeutics (LCTX) has a market cap of $394M as of March 13, 2026.
What is the P/E ratio for Lineage Cell Therapeutics stock?
The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of March 13, 2026.
Does Lineage Cell Therapeutics stock pay dividends?
No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Lineage Cell Therapeutics dividend payment date?
Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.